SBI Biotech ^Company

SBI Biotech is a bio-venture company that specializes in dendritic cell platform-based drug development. They focus on early stages of drug development due to limited resources and aim to license their pipelines in the preclinical stage to efficiently use their resources. They have a world-leading research team with expertise in dendritic cell manipulation and have successfully licensed their early stage dendritic cells targeting antibody to MedImmune. SBI Biotech is a clinical-stage biopharmaceutical company group focused on developing novel therapeutics based on RNAi technology and a unique cell line of Plasmacytoid Dendritic Cells.